Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
-
Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (2)
June 27, 2005
-
Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (1)
June 20, 2005
-
Special Contribution
May 16, 2005
-
Japan's Most Admired Pharma Companies P. Reed Maurer President, NPP
April 18, 2005
-
PRTM Shows Results of Investigational Drug Survey
March 14, 2005
-
＜Special Comtribution＞
March 7, 2005
-
＜Special Comtribution＞
March 7, 2005
-
JPMA Update (12)
November 22, 2004
-
JPMA Pudate(11)
November 15, 2004
-
JPMA Update (10)
November 8, 2004
-
JPMA Update (9)
November 1, 2004
-
JPMA Update (8)
October 25, 2004
-
JPMA Update (7)
October 18, 2004
-
JPMA Update (6)
October 11, 2004
-
＜Special Contribution＞
October 4, 2004
-
JPMA Update (5)
October 4, 2004
-
JPMA Update(4)
September 27, 2004
-
JPMA Update (3)
September 20, 2004
-
JPMA Update (2)
September 13, 2004
-
＜New Series＞
September 6, 2004
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…